Systems often track āMAT utilizationā while missing the mechanics that determine whether medication continuity actually happens. People fall out of treatment not only because of motivation, but because workflows break: prescriber wait times, prior authorization delays, pharmacy handoffs, missed-dose follow-up, and transitions between settings that reset the process. Continuous improvement for MAT requires measures that mirror those bottlenecksāand an operating rhythm that changes how teams work week to week.
In Outcomes, Quality Measures & Continuous Improvement, MAT should be measured in ways that strengthen Community-Based SUD Service Models: fast access for high-risk referrals, reliable follow-up, and transition integrity so medication does not stop when care settings change.
What to measure if you want MAT continuity (not just MAT āon paperā)
MAT measurement should distinguish access (how quickly someone can start), continuity (whether medication continues without avoidable gaps), and retention support (how the system responds when someone destabilizes). Useful measures include time-to-prescriber contact, time-to-first dose, pharmacy pickup continuity, follow-up after missed doses, and post-transition medication verification.
Expectation 1: oversight expects documentation of access pathways and timeliness
Funders and commissioners typically expect to see evidence that access is operationalized: clear referral routes, triage rules for high-risk individuals, and defined timeliness standards. A system that cannot show how it prioritizes overdose risk or pregnancy, for example, may be seen as lacking due diligenceāeven if overall āutilizationā looks acceptable.
Expectation 2: governance expects medication continuity safeguards during transitions
Oversight increasingly focuses on transitions (detox, ED, inpatient, incarceration release) where medication disruption is common. Systems are expected to have safeguards: verification steps, handoff protocols, and follow-up windows that prevent inadvertent gaps. Measurement should prove those safeguards are applied consistently, not just written in policy.
Design measures around the failure points: prescriber, payer, pharmacy, and follow-up
MAT continuity can fail at four points: prescriber availability, payer authorization, pharmacy fulfillment, and follow-up after missed contact or missed dosing. A strong CQI approach maps these failure points and assigns measures and owners for each, so improvement work isnāt diffuse.
Operational example 1: a ātime-to-first-doseā pathway tracker that identifies where access is really getting stuck
What happens in day-to-day delivery: For each new MAT referral, the team tracks a small set of timestamps: referral received, first outreach attempt, first successful contact, prescriber appointment scheduled, prescriber contact completed, first dose issued, and first pharmacy pickup (where applicable). A supervisor reviews the tracker weekly, looking for common delays (e.g., scheduling bottlenecks, incomplete paperwork, payer steps). The team tests one change at a timeāsuch as reserving same-day prescriber slots for high-risk referrals or standardizing intake documentation to reduce rescheduling.
Why the practice exists (failure mode it addresses): Systems often assume delays are ābecause of the prescriberā or ābecause of the patient,ā but the real causes can be administrative: missing documentation, unclear triage, or delays between outreach and scheduling. The tracker exists to reveal the true bottleneck and connect improvement work to a measurable workflow step.
What goes wrong if it is absent: Leaders canāt see where time is being lost, so improvement becomes guesswork. People wait too long, disengage, or return to high-risk use while āon the list.ā The system experiences avoidable overdoses or ED use, yet cannot evidence which step failed or how to fix it.
What observable outcome it produces: Reduced time-to-first meaningful contact, shorter time-to-first dose, and clearer evidence of where process changes improved throughput. Evidence includes weekly tracker trends, reductions in āstalledā cases, and improved initiation rates for high-risk cohorts.
Build continuity measures that detect early drift
Retention is often measured at 30 or 90 days, but continuity drift appears earlier: missed pharmacy pickups, missed follow-up appointments, or missed doses without outreach. Systems should measure early warning indicators and treat them as safety-adjacentābecause gaps can trigger rapid destabilization.
Operational example 2: a missed-dose follow-up standard that prevents silent drop-off
What happens in day-to-day delivery: The service defines a missed-dose / missed pickup follow-up standard. When a pickup is missed (or a dosing appointment is missed), the peer or care coordinator initiates a structured outreach sequence within 24 hours: call/text, same-day check-in attempt, and a follow-up attempt the next day if needed. If contact is not made within a defined window, the case is escalated to a supervisor huddle for a decision: home visit attempt where appropriate, partner notification (with consent), or a safety plan review if risk is high. All actions are recorded in a simple follow-up log reviewed weekly.
Why the practice exists (failure mode it addresses): People often fall out of MAT not through formal discharge but through āsilent dropoutāāmissed doses without timely re-engagement. This practice exists to prevent slow disengagement, reduce overdose risk, and make re-engagement a supervised routine rather than an ad hoc effort.
What goes wrong if it is absent: Missed doses accumulate without response, staff assume the person āchose to disengage,ā and medication discontinuity becomes normalized. The system then sees preventable crisis events, re-referrals, or justice involvement, with no clear evidence of timely outreach or escalation.
What observable outcome it produces: Higher re-engagement rates after missed doses, fewer extended medication gaps, and improved retention at 30/90 days. Evidence includes follow-up log completion, timeliness of outreach, reductions in repeated missed pickups, and improved continuity metrics.
Transitions: measure verification, not assumptions
Transitions are a high-risk moment for medication disruption. Measurement must confirm what happened: was medication continued, was a bridge prescription secured, was a prescriber appointment arranged, and was the person reached after transition? āReferral sentā is not continuity.
Operational example 3: post-transition medication verification within 72 hours for high-risk discharges
What happens in day-to-day delivery: For individuals leaving detox, ED, inpatient, or custody with MAT needs, the system applies a 72-hour verification standard. A coordinator confirms: medication plan at discharge, bridge supply (if applicable), pharmacy details, next prescriber contact, and whether the person has transportation or other barriers. The coordinator conducts a direct check-in within the window and records confirmation (or issues) in a transition tracker. If verification fails (no contact, medication not obtained, appointment not scheduled), the case is escalated immediately to the supervisor huddle and partner pathway leads.
Why the practice exists (failure mode it addresses): Transitions fail when teams assume continuity will happen because it was written in a discharge plan. The verification standard exists to prevent medication gaps created by broken handoffs, incomplete information, or practical barriers (transport, ID, pharmacy access) that derail continuity within days.
What goes wrong if it is absent: People leave a setting with a plan that is not executed. Medication stops, withdrawal and relapse risk rises quickly, and the system experiences repeat ED use or overdose risk escalation. When asked what happened, providers can only say āwe referred,ā with no proof of continuity checks.
What observable outcome it produces: Higher rates of confirmed medication continuation, fewer post-transition gaps, and reduced repeat crisis contacts linked to disrupted MAT. Evidence includes transition tracker completion, verified continuity rates, faster resolution of barriers, and fewer repeated ED presentations among the transition cohort.
Use CQI cycles that fit MAT realities
MAT improvement often requires small, rapid cycles: a scheduling change, a documentation standard, a pharmacy coordination step, or a follow-up cadence. Systems should test changes quickly, measure results within weeks, then standardize and audit adoption. The goal is reliable medication continuityānot just improved reporting.